Table 1.
Top 10 most-cited articles on renal cell carcinoma.
| Rank | Title | First author | Citation | Year | Average per yr (rank) |
|---|---|---|---|---|---|
| 1 | Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Motzer, RJ | 4530 | 2007 | 283.1(4) |
| 2 | Sorafenib in advanced clear-cell renal-cell carcinoma | Escudier, B | 3883 | 2007 | 242.7 (6) |
| 3 | Nivolumab versus everolimus in advanced renal-cell carcinoma | Motzer, RJ | 3587 | 2015 | 448.4 (1) |
| 4 | Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Hudes, G | 2973 | 2007 | 185.8 (8) |
| 5 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial | Motzer, RJ | 2382 | 2008 | 158.8 (10) |
| 6 | Prognostic significance of morphologic parameters in renal cell carcinoma | Fuhrman, SA | 2177 | 1982 | 53.1 (50) |
| 7 | A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Yang, JC | 2168 | 2003 | 108.4 (19) |
| 8 | Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma | Motzer, RJ | 1954 | 2018 | 390.8 (2) |
| 9 | Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial | Sternberg, CN | 1859 | 2010 | 143 (12) |
| 10 | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial | Escudier, B | 1841 | 2007 | 115.06 (17) |